Core Viewpoint - Fulejia, known as the "first stock of medical beauty masks," is facing significant challenges, with a reported revenue decline of 11.54% year-on-year for the first three quarters of 2025, totaling 1.297 billion yuan. The company aims to achieve at least 700 million yuan in revenue in the fourth quarter, which appears to be a considerable challenge [2]. Group 1: Business Performance and Challenges - Fulejia's revenue for the full year of 2024 was 2.017 billion yuan, indicating a need for substantial growth in Q4 2025 to meet targets [2]. - The company's medical device product revenue share has decreased from 55.54% in 2020 to 42.28% in 2024, and further down to 27.61% in the first half of 2025, highlighting a significant impact on its financial performance [9]. - The tightening of regulations regarding "medical beauty masks" has created a clearer distinction between medical devices and cosmetic products, further complicating Fulejia's market position [6][7]. Group 2: Product Development and Market Strategy - Fulejia has made progress in its Class III medical device projects, with a new product, "recombinant type III humanized collagen dressing," entering clinical stages, while other products are in various stages of development [2][4]. - The shift towards Class III medical devices is part of a broader trend among beauty brands, as many are moving away from Class II products due to market saturation and regulatory challenges [3][4]. - Fulejia's entry into the Class III market is seen as a strategy to strengthen its position in the medical beauty sector, although it is currently lagging behind competitors who have already secured Class III registrations [4]. Group 3: Transition to Cosmetics - Fulejia's cosmetics business has seen growth, with revenue surpassing that of medical devices for the first time in 2022, indicating a strategic pivot [11]. - However, the brand still faces challenges in changing consumer perceptions from a medical mask brand to a cosmetics brand, as many consumers associate Fulejia primarily with medical beauty masks [12]. - The company has encountered complaints regarding its cosmetic products, raising concerns about safety and efficacy, which could hinder its ability to attract new customers [12]. Group 4: Research and Development - Fulejia's R&D investment for the first three quarters of 2025 was 36.31 million yuan, with a R&D expense ratio of 2.8%, which, while improved, remains low compared to competitors [14]. - The company holds a total of 61 patents, but the majority are design patents, indicating a potential weakness in innovation compared to peers in the beauty industry [14]. - Balancing R&D investments between medical devices and cosmetics presents a challenge for Fulejia, as both sectors require significant resources to remain competitive [16].
敷尔佳开启转型，医美+美妆能否带来新增长？